This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MDX-1103, MEDI545, MEDI-545
Description: MEDI-545 is a fully human monoclonal antibody (MAb) targeting interferon-alpha. Published preclinical data indicate that levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE or lupus) and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.
Deal Structure: In November 2004, MedImmune and Medarex entered into a collaboration to develop antibodies targeting interferon-alpha and the type I interferon receptor 1. The collaboration will initially focus on two antibodies, MDX-1103 and MDX-1333. Under the terms of the agreement, Medarex will receive an upfront payment of $15 million. MedImmune will be fully responsible for the continued development of the product candidates. Prior to the beginning of pivotal studies, Medarex may elect to co-develop the products in return for the opportunity to co-promote and to receive a share of the commercial profits in the United States. In all other cases, Medarex will be entitled to receive milestone payments and royalties.
In June 2007, AstraZeneca closed its acquisition of MedImmune.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: